

RESEARCH ARTICLE

Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort

Ross McQueenie^{1‡}, Hamish M. E. Foster^{1‡}, Bhautesh D. Jani¹, Srinivasa Vittal Katikireddi¹, Naveed Sattar², Jill P. Pell¹, Frederick K. Ho¹, Claire L. Niedzwiedz¹, Claire E. Hastie¹, Jana Anderson¹, Patrick B. Mark², Michael Sullivan², Catherine A. O'Donnell¹, Frances S. Mair^{1‡}, Barbara I. Nicholl^{1‡*}

1 Institute of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, **2** British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom

‡ RM and HMEF share first authorship on this work. FSM and BIN are joint senior authors on this work.

* barbara.nicholl@glasgow.ac.uk



Abstract

OPEN ACCESS

Citation: McQueenie R, Foster HME, Jani BD, Katikireddi SV, Sattar N, Pell JP, et al. (2020) Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort. PLoS ONE 15(8): e0238091. <https://doi.org/10.1371/journal.pone.0238091>

Editor: Ying-Mei Feng, Beijing Key Laboratory of Diabetes Prevention and Research, CHINA

Received: June 11, 2020

Accepted: August 9, 2020

Published: August 20, 2020

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0238091>

Copyright: © 2020 McQueenie et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: The data in this study is owned by the UK Biobank (www.ukbiobank.ac.uk) and as researchers we are not entitled to republish or otherwise make available any UK

Background

It is now well recognised that the risk of severe COVID-19 increases with some long-term conditions (LTCs). However, prior research primarily focuses on individual LTCs and there is a lack of data on the influence of multimorbidity (≥ 2 LTCs) on the risk of COVID-19. Given the high prevalence of multimorbidity, more detailed understanding of the associations with multimorbidity and COVID-19 would improve risk stratification and help protect those most vulnerable to severe COVID-19. Here we examine the relationships between multimorbidity, polypharmacy (a proxy of multimorbidity), and COVID-19; and how these differ by sociodemographic, lifestyle, and physiological prognostic factors.

Methods and findings

We studied data from UK Biobank (428,199 participants; aged 37–73; recruited 2006–2010) on self-reported LTCs, medications, sociodemographic, lifestyle, and physiological measures which were linked to COVID-19 test data. Poisson regression models examined risk of COVID-19 by multimorbidity/polypharmacy and effect modification by COVID-19 prognostic factors (age/sex/ethnicity/socioeconomic status/smoking/physical activity/BMI/systolic blood pressure/renal function). 4,498 (1.05%) participants were tested; 1,324 (0.31%) tested positive for COVID-19. Compared with no LTCs, relative risk (RR) of COVID-19 in those with 1 LTC was no higher (RR 1.12 (CI 0.96–1.30)), whereas those with ≥ 2 LTCs had 48% higher risk; RR 1.48 (1.28–1.71). Compared with no cardiometabolic LTCs, having 1 and ≥ 2 cardiometabolic LTCs had a higher risk of COVID-19; RR 1.28 (1.12–1.46) and 1.77 (1.46–2.15), respectively. Polypharmacy was associated with a dose response higher risk of COVID-19. All prognostic factors were associated with a higher risk of COVID-19 infection in multimorbidity; being non-white, most socioeconomically deprived, BMI ≥ 40 kg/m², and reduced renal function were associated with the highest risk of COVID-19 infection: RR 2.81 (2.09–3.78); 2.79 (2.00–3.90); 2.66 (1.88–3.76); 2.13 (1.46–3.12), respectively. No

Biobank data at the individual participant level (<https://www.ukbiobank.ac.uk/wpcontent/uploads/2013/10/ukbiobank-data-management.pdf>). However, any bona fide researcher can apply to use the UK Biobank resource for health-related research that is in the public interest by following the registration and access link <https://bbams.ndph.ox.ac.uk/ams/>.

Funding: The author(s) received no specific funding for this work.

Competing interests: JPP is a member of the Scientific Advisory Committee of UK Biobank. This does not alter our adherence to PLOS ONE policies on sharing data and materials. All other authors have no potential, perceived, or real conflicts of interest.

multiplicative interaction between multimorbidity and prognostic factors was identified. Important limitations include the low proportion of UK Biobank participants with COVID-19 test data (1.05%) and UK Biobank participants being more affluent, healthier and less ethnically diverse than the general population.

Conclusions

Increasing multimorbidity, especially cardiometabolic multimorbidity, and polypharmacy are associated with a higher risk of developing COVID-19. Those with multimorbidity and additional factors, such as non-white ethnicity, are at heightened risk of COVID-19.

Introduction

COVID-19 is an ongoing pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1–3]. COVID-19 clinical manifestations range from asymptomatic and mild upper respiratory symptoms to severe respiratory failure and death [4]. A range of prognostic factors for greater mortality from COVID-19 have been identified including age [5], male sex [6], non-white ethnicity [7], obesity [8], pre-existing long-term conditions (LTCs; e.g. hypertension [9], diabetes [10], chronic kidney disease [11]), and multimorbidity (presence of ≥ 2 LTCs) [11–13]. As a result, a key mitigation strategy in many countries is the identification and protection of those deemed vulnerable or at higher risk of adverse outcomes [14].

For example, in both the UK and the USA, age (≥ 70 in UK and ≥ 65 in USA), severe obesity (BMI ≥ 40 kg/m²), being immunocompromised, and certain LTCs (e.g. cardiac/respiratory/renal disease) are used to identify those at higher risk of severe disease [14, 15]. Individuals who meet any of these criteria have been asked to be more cautious and adhere to public health guidance (e.g. social distancing) more strictly than the general population. In the UK, this higher-risk group is distinct from those with specific LTCs (e.g. leukaemia) who are considered ‘extremely high risk’ and, as a result, are asked to ‘shield’ and not leave their homes at all [16].

To date, LTC prognostic factors for severe COVID-19 primarily involve single conditions and there is a lack of data on the influence of multimorbidity on the risk of COVID-19 [5, 13, 17]. Multimorbidity prevalence is increasing worldwide and is associated with higher mortality, with different disease clusters associated with even higher mortality [18–21]. Polypharmacy, closely linked to multimorbidity [22], is also associated with adverse health outcomes [23]. Therefore, it is plausible that the number of LTCs, type of LTCs, and polypharmacy are associated with a higher risk of developing severe COVID-19. Furthermore, it is plausible that the adverse consequences of multimorbidity on COVID-19 risk may be greater for population subgroups (e.g. people aged ≥ 65 years, or those with a BMI ≥ 40 kg/m²). Such knowledge would benefit clinicians, as this is routinely collected information in many clinical settings. Using a large UK population cohort, UK Biobank, we aimed to investigate:

1. the association between multimorbidity (by number and type of LTC, and by level of polypharmacy) and COVID-19.
2. the potential effect modification of known COVID-19 sociodemographic and physiological risk factors on the association between multimorbidity and COVID-19.

Methods

Study design and data collection

Data came from UK Biobank, a longitudinal population-based cohort of 502,503 participants aged between 37–73 years old at baseline from England, Wales and Scotland [24]. Baseline data were collected across 22 assessment centres between 2006–2010. UK Biobank contains detailed biological measurements and self-reported demographic, lifestyle, and health information elicited by touch-screen questionnaire and nurse-led interview. COVID-19 test samples were collected and processed between 16 March 2020 and 18th May 2020. COVID-19 test results were provided by Public Health England (PHE) [25]. Data presented here are from participants recruited from 16 assessment centres located in England only (5 participants with COVID-19 test data were excluded as they attended baseline assessment centres in Scotland or Wales). Participants who had died prior to the last available mortality register extraction (14 February 2018) were also excluded. This resulted in a final eligible study population of 428,199 participants.

This study was conducted as part of UK Biobank project number 14151 and is covered by the generic ethics approval for UK Biobank studies from the NHS National Research Ethics Service (16/NW/0274).

Outcomes

Our outcome of interest was confirmed COVID-19 infection (defined as at least one positive test result). Whether or not participants received a COVID-19 test was used as an outcome for a secondary analysis, presented in Supplementary Material (S1–S3 Tables).

Measurement of LTCs

Physician-diagnosed LTCs were self-reported and confirmed at nurse-led interview at baseline. Number of LTCs, based on 43 commonly occurring LTCs from previous UK Biobank work [21], were categorised into 0, 1, and ≥ 2 . When used as a predictor variable for COVID-19, LTCs were modelled using three measures: total number of LTCs; number of cardiometabolic LTCs (diabetes, coronary heart disease, atrial fibrillation, chronic heart failure, chronic kidney disease, hypertension, stroke/transient ischaemic attack, or peripheral vascular disease); and number of respiratory LTCs (asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema, or bronchiectasis).

Measurement of polypharmacy

Participant medication numbers were based on self-report at baseline and categorised into: 0, 1–3, 4–6, 7–9 and, ≥ 10 medications.

Exposures

As for LTC and polypharmacy measures, all exposures were based on assessment at the time of recruitment. Sex was collected as a binary variable (male/female). Age at time of COVID-19 test was calculated using age at baseline, and dates of baseline assessment and COVID-19 test extract, and categorised as 48–59, 60–69, and 70–86 years. Ethnicity was self-reported and categorised as Asian/Asian British, black/black British, Chinese, mixed, white and other. Socio-economic deprivation was measured using the Townsend score of participants' postcode of residence derived from Census data on car ownership, household occupancy, unemployment, and occupation and categorised into quintiles [26]. Smoking status was dichotomised as never and current/former. Frequency of alcohol intake was categorised into: "Never or special

occasions only”, “1–3 times a month”, “1–4 times a week”, or “Daily or almost daily”. Level of physical activity was defined as “none”, “low”, “medium”, or “high” using Metabolic Equivalent Task (MET) scores based on the International Physical Activity Questionnaire (IPAQ) scoring protocol [27]. Assessment centre location, a categorical variable, describes attendance at one of sixteen assessment centres included in this study. BMI was derived from weight and height and categorised as <18.5, 18.5–25, 25–30, 30–35, or >35 kg/m². The UK Biobank study protocol is described in more detailed online [28].

To assess potential effect modification on the association between multimorbidity and COVID-19, known COVID-19 risk factors were re-categorised into dichotomous variables based on at-risk status: age (</≥65 years), ethnicity (white/non-white), physical activity (</≥ current UK guidelines of 150 min/week moderate or 75 min/week vigorous physical activity) [29], and BMI (</≥40kg/m²; severely obese) [15]. Due to previously identified associations with severe COVID-19, two additional physiological risk factors were also included in this analysis: raised systolic blood pressure (</≥140 mmHg) as a marker of hypertension [9]; and reduced estimated glomerular filtration rate (eGFR; </≥60 ml/min/1.73 m²), with <60 ml/min/1.73 m² used as a marker of chronic kidney disease [30]. eGFR was calculated by the CKD-EPI equation [31].

Statistical analyses

We compared participants who tested positive for COVID-19 with those who tested negative or were not tested, based on sociodemographics (age, sex, Townsend score and ethnicity), lifestyle (smoking status, frequency of alcohol intake, physical activity), BMI, LTCs, and medication counts using χ^2 tests. Poisson regression models were then used to test for an association between outcome measure (confirmed COVID-19 infection vs. no COVID-19 infection, including those with a negative result and those not tested) and number of LTCs (all, cardiometabolic and respiratory LTCs)/level of polypharmacy. We chose Poisson regression models rather than logistic regression to provide more interpretable relative risks as opposed to odds ratios [32]. Participants with no LTCs, no cardiometabolic LTCs, no respiratory LTCs, or not taking any medication formed the respective reference groups. Two models were conducted, adjusting for 1) sociodemographic variables (as above plus assessment centre location), and 2) as for model 1 adjustments plus lifestyle variables and BMI. For both χ^2 tests and Poisson regression models, $p < 0.01$ was considered statistically significant.

Next, we assessed whether there was evidence of effect modification on an additive scale by examining how the association between multimorbidity and COVID-19 differed across strata of known COVID-19 risk factors: sex, age, ethnicity, Townsend score, smoking, physical activity, BMI, systolic blood pressure, and eGFR. For each risk factor, the reference category was participants in the lowest risk category for that risk factor who also had no LTCs. We used Poisson regression models to examine the association between LTC and COVID-19 across the other combinations of LTC and risk factor categories. We tested formally for interactions by performing ANOVA tests between two models for each risk factor: one model containing an interaction term between the risk factor and number of LTCs, and one without the interaction term. Interactions were considered significant if $p < 0.01$ for each ANOVA. As a secondary analysis we re-ran the analyses with the outcome as tested vs. not tested for COVID-19. The number of participants in each model varied depending on the proportion missing data for any included variable, however, the maximum proportion of missing data for any variable of interest was 2.9% (N = 12,350) for systolic blood pressure. All analyses were conducted using R studio v.1.2.1335 operating R v.3.6.1.

Results

Demographic and lifestyle factors

Of 428,199 eligible participants, 1,324 (0.31%) tested positive for COVID-19. Participants who tested positive for COVID-19 were older and more likely to be male, non-white, in the most deprived quintile, current/former smokers, drink alcohol rarely, to have a BMI of ≥ 40 kg/m², do no physical activity, to have more LTCs (including cardiometabolic and respiratory LTCs), and to be taking more medications, compared to those who did not have a positive COVID-19 test (Table 1).

Table 1. Cohort characteristics by COVID-19 test positive or not.

	COVID-19 test negative or not tested (n = 426,875)	COVID-19 test positive (n = 1,324)
Sex		
Female	234,507	628
	54.9 %	47.4 %
Male	192,368	696
	45.1 %	52.6 %
Age at COVID-19 test (years)		
48–59	94,652	381
	22.2 %	28.8 %
60–69	139,817	307
	32.8 %	23.2 %
70–86	192,406	636
	45.1 %	48.0 %
Ethnicity		
White	399,388	1,139
	94.1 %	86.7 %
Asian or Asian British	9,186	60
	2.2 %	4.6 %
Black or Black British	7,650	76
	1.8 %	5.8 %
Chinese	1,396	6
	0.3 %	0.5 %
Mixed	2,652	9
	0.6 %	0.7 %
Other ethnic group	4,181	23
	1.0 %	1.8 %
Townsend quintile		
1 (least deprived)	84,840	179
	19.9 %	13.5 %
2	86,510	207
	20.3 %	15.6 %
3	85,788	222
	20.1 %	16.8 %
4	85,402	290
	20.0 %	21.9 %
5 (most deprived)	83,835	425
	19.7 %	32.1 %

(Continued)

Table 1. (Continued)

	COVID-19 test negative or not tested	COVID-19 test positive
	(n = 426,875)	(n = 1,324)
Smoking status		
Never	235,056	642
	55.4 %	49 %
Current or Previous	189,299	669
	44.6 %	51.0 %
Frequency of alcohol intake		
Never or special occasions only	82,785	363
	19.5 %	27.5 %
One to three times a month	47,535	183
	11.2 %	13.9 %
One to four times a week	208,046	563
	48.9 %	42.7 %
Daily or almost daily	87,211	209
	20.5 %	15.9 %
Physical activity level		
None	25,887	157
	6.2 %	12.2 %
Low	15,687	51
	3.7 %	4.0 %
Medium	335,775	957
	79.8 %	74.5 %
High	43,383	120
	10.3 %	9.3 %
BMI (kg/m²)		
<18.5	2,138	7
	0.5 %	0.5 %
18.5–25	135,563	297
	31.9 %	22.7 %
25–30	182,243	551
	42.9 %	42.1 %
30–35	75,201	282
	17.7 %	21.5 %
≥35	29,210	172
	6.9 %	13.1 %
Number of long-term conditions		
0	148,826	351
	35.0 %	26.8 %
1	139,963	385
	32.9 %	29.4 %
≥ 2	136,508	572
	32.1 %	43.7 %
Number of cardiometabolic long-term conditions		
0	300,363	773
	70.4 %	58.4 %
1	103,185	394
	24.2 %	29.8 %

(Continued)

Table 1. (Continued)

	COVID-19 test negative or not tested	COVID-19 test positive
	(n = 426,875)	(n = 1,324)
≥ 2	23,327	157
	5.5 %	11.9 %
Number of respiratory long-term conditions		
0	373,026	1,120
	87.4 %	84.6 %
1	51,226	186
	12.0 %	14.0 %
≥ 2	2,623	18
	0.6 %	1.4 %
Number of medications		
0	121,288	296
	28.5 %	22.4 %
1–3	197,296	526
	46.3 %	39.8 %
4–6	76,265	298
	17.9 %	22.5 %
7–9	22,779	130
	5.3 %	9.8 %
≥ 10	8,538	72
	2 %	5.4 %

This table uses participants with COVID-19 positive tests as positive group and all other participants as negative group. All chi squared tests $p < 0.01$.

<https://doi.org/10.1371/journal.pone.0238091.t001>

Multimorbidity and COVID-19

In the fully adjusted model (Model 2), compared to those with no LTCs, participants with 1 LTC had no higher risk of having a positive test for COVID-19 (RR 1.12 (0.96–1.30) $p = 0.15$), but those with ≥ 2 LTCs had a 48% higher risk (RR 1.48 (1.28–1.71) $p < 0.01$) (Table 2). Compared to those with no cardiometabolic LTCs, those with 1 cardiometabolic LTC had a 28% higher risk (RR 1.28 (1.12–1.46) $p < 0.01$), and those with ≥ 2 cardiometabolic LTCs had a 77% higher risk (RR 1.77 (1.46–2.15) $p < 0.01$) (Table 2). Participants with one respiratory LTC had no greater risk of a positive COVID-19 test compared to those with no respiratory LTCs (RR 1.14 (0.97–1.33) $p = 0.12$; Table 2). There was a higher risk of having a positive COVID-19 test in those with ≥ 2 respiratory LTCs (RR 1.78 (1.10–2.88) $p = 0.02$) compared to 0 respiratory LTCs but this did not meet our p -value threshold of 0.01. However, it is a similar higher risk observed (78%) as for participants with ≥ 2 cardiometabolic conditions (77%); the lack of statistical significance may be explained by the much lower number of participants in the group with ≥ 2 respiratory LTCs ($N = 2,641$) compared to ≥ 2 cardiometabolic conditions ($N = 23,484$).

Polypharmacy and COVID-19

Compared to those taking no medications, in the fully adjusted model (Model 2) there was a clear dose relationship whereby the risk of a COVID-19 positive test rose steadily with polypharmacy level (Table 2): 4–6 medications (RR 1.41 (1.18–1.67) $p < 0.01$); 7–9 medications (RR 1.86 (1.49–2.33) $p < 0.01$); and ≥ 10 medications (RR 2.42 (1.82–3.21) $p < 0.01$).

Table 2. Relative risk of positive COVID-19 test by LTC groups (Poisson regression).

Measure of Multimorbidity (n)	Model 1 RR (95% CI)	P value	Model 2 RR (95% CI)	P value
Total number of LTCs				
0 (149,177)	1 (ref)	-	1 (ref)	-
1 (140,348)	1.18 (1.02–1.36)	0.03	1.12 (0.96–1.30)	0.15
≥2 (137,080)	1.73 (1.51–1.99)	***	1.48 (1.28–1.71)	***
Number of cardiometabolic LTCs				
0 (301,136)	1 (ref)	-	1 (ref)	-
1 (103,579)	1.41 (1.24–1.60)	***	1.28 (1.12–1.46)	***
≥2 (23,484)	2.17 (1.82–2.60)	***	1.77 (1.46–2.15)	***
Number of respiratory LTCs				
0 (374,146)	1 (ref)	-	1 (ref)	-
1 (51,412)	1.20 (1.03–1.41)	0.02	1.14 (0.97–1.33)	0.12
≥2 (2,641)	2.09 (1.31–3.33)	***	1.78 (1.10–2.88)	0.02
Number of medications				
0 (121,584)	1 (ref)	-	1 (ref)	-
1–3 (192,822)	1.13 (0.98–1.31)	0.10	1.07 (0.93–1.24)	0.36
4–6 (76,563)	1.58 (1.34–1.87)	***	1.41 (1.18–1.67)	***
7–9 (22,909)	2.24 (1.81–2.77)	***	1.86 (1.49–2.33)	***
≥ 10 (8,610)	3.09 (2.37–4.03)	***	2.42 (1.82–3.21)	***

Model 1: Adjusted for age, sex, Townsend score, ethnicity, and assessment centre location. Model 2: As model 1 and additionally adjusted for smoking status, alcohol intake frequency, BMI, and physical activity. RR = Relative risk; CI = confidence interval; n = number of participants; LTC = long-term condition; Cardiometabolic LTC = diabetes, coronary heart disease, atrial fibrillation, chronic heart failure, chronic kidney disease, hypertension, stroke/TIA or peripheral vascular disease; Respiratory LTC = asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema, or bronchiectasis.

***p<0.01 Note: These results show the RR of a positive COVID-19 test versus a negative COVID-19 test or not tested (counterfactual group contains both participants who have a negative COVID-19 test result and participants who were not tested (n = 426,875)).

<https://doi.org/10.1371/journal.pone.0238091.t002>

Interactions between COVID-19 prognostic factors and multimorbidity

For all risk factors examined, there was a general trend of higher risk of a positive COVID-19 test with increasing LTCs and at-risk subgroups (Fig 1; Table 3). Further, for all prognostic factors, in participants with ≥2 LTCs there was a higher risk of a positive COVID-19 test for each risk factor subgroup when examining ethnicity, physical activity, BMI, systolic blood pressure, and eGFR. For some factors, having ≥2 LTCs was associated with an increased risk of COVID-19 infection only in the at-risk sub-group: males when examining sex; >65 years when examining age; and current/previous smoker when examining smoking status. When observing the effect of socioeconomic status, significantly higher risk of COVID-19 infection was apparent in the more deprived quintiles. There was no evidence of a multiplicative interaction between all risk factors modelled and number of LTCs. However, there appeared to be an additive effect whereby the combination of multimorbidity and each prognostic factor was associated with greater risk of COVID-19 infection. Of those with no LTCs, being ≥65 years old was associated with 34% lower risk of COVID-19 compared with those <65 years old.

Similar results overall were observed in the secondary analysis, where the above analyses were repeated in those who were tested for COVID-19 versus those who were not (S1–S3 Tables).




Fig 1. Relative risk of positive COVID-19 test by long-term condition count and prognostic factors (Poisson regression). Prognostic factors: a) Sex, b) Age (years), c) Ethnicity, d) Townsend quintile (1 least deprived; 5 most deprived), e) Smoking status, f) Physical activity level (based on UK guidelines), g) Body-mass index (BMI; kg/m^2), h) Systolic blood pressure (mmHg), and i) estimated glomerular filtration rate (eGFR; $\text{ml}/\text{min}/1.73\text{m}^2$). Models were adjusted for sex, age, ethnicity, Townsend score, smoking status, alcohol intake frequency, physical activity, BMI, and assessment centre location.

<https://doi.org/10.1371/journal.pone.0238091.g001>

Table 3. Relative risk of positive COVID-19 test by LTC count and prognostic factors (Poisson regression).

Prognostic factor	LTC count	Prognostic factor subgroup	N	Relative risk (95% CI)	P value
Sex	0	Female	80,212	1 (ref)	
		Male	68,965	1.08 (0.87–1.33)	0.51
	1	Female	76,383	0.95 (0.77–1.18)	0.67
		Male	63,965	1.39 (1.13–1.71)	***
	≥2	Female	77,492	1.24 (1.01–1.51)	0.04
		Male	59,588	1.88 (1.54–2.29)	***
Age at COVID-19 test (years)	0	< 65	16,470	1 (ref)	
		≥ 65	132,707	0.66 (0.53–0.82)	***
	1	< 65	25,029	1.07 (0.87–1.31)	0.51
		≥ 65	115,319	0.82 (0.68–1.00)	0.05
	≥2	< 65	36,865	0.99 (0.79–1.25)	0.96
		≥ 65	100,215	1.29 (1.09–1.53)	***
Ethnicity	0	White	138,677	1 (ref)	
		Other	9,492	1.84 (1.34–2.54)	***
	1	White	131,644	1.10 (0.94–1.29)	0.24
		Other	8,055	2.28 (1.67–3.11)	***
	≥2	White	129,033	1.47 (1.26–1.72)	***
		Other	7,408	2.81 (2.09–3.78)	***
Townsend quintile (1-least deprived; 5-most deprived)	0	1	30,995	1 (ref)	
		2	31,206	1.24 (0.84–1.82)	0.28
		3	30,394	1.19 (0.80–1.75)	0.39
		4	29,633	1.46 (1.01–2.12)	0.04
		5	26,956	1.96 (1.37–2.80)	***
	1	1	28,723	1.47 (1.00–2.14)	0.05
		2	28,898	1.34 (0.92–1.97)	0.13
		3	28,605	1.39 (0.95–2.04)	0.09
		4	27,950	1.79 (1.25–2.46)	***
		5	26,005	1.79 (1.19–2.70)	***
	≥2	1	25,310	1.57 (1.07–2.30)	0.02
		2	26,585	1.75 (1.21–2.52)	***
		3	26,771	1.77 (1.23–2.55)	***
		4	27,764	2.22 (1.57–3.15)	***
		5	20,670	2.79 (2.00–3.90)	***
Smoking status	0	never	88,737	1 (ref)	
		current/previous	59,500	1.26 (1.02–1.57)	0.03
	1	never	77,915	1.18 (0.96–1.44)	0.11
		current/previous	61,781	1.33 (1.08–1.65)	0.01
	≥2	never	68,324	1.39 (1.14–1.70)	***
	current/previous	67,956	1.97 (1.62–2.38)	***	
Physical activity level	0	≥ guidelines	80,715	1 (ref)	
		< guidelines	36,507	1.44 (1.09–1.91)	0.01
	1	≥ guidelines	74,324	1.32 (0.94–1.83)	0.11
		< guidelines	32,998	1.51 (1.13–2.00)	***
	≥2	≥ guidelines	68,226	1.87 (1.40–2.67)	***
	< guidelines	29,622	1.95 (1.43–2.67)	***	

(Continued)

Table 3. (Continued)

Prognostic factor	LTC count	Prognostic factor subgroup	N	Relative risk (95% CI)	P value
BMI (kg/m ²)	0	<40	146,986	1 (ref)	
		≥40	1,094	1.30 (0.49–3.50)	0.60
	1	<40	137,865	1.14 (0.99–1.33)	0.08
		≥40	1,912	1.34 (0.63–2.85)	0.44
	≥2	<40	131,416	1.54 (1.33–1.78)	***
		≥40	4,865	2.66 (1.88–3.76)	***
Systolic blood pressure (mm Hg)	0	<140	97,526	1 (ref)	
		≥140	47,162	0.88 (0.69–1.11)	0.28
	1	<140	78,786	1.10 (0.91–1.32)	0.33
		≥140	57,921	1.04 (0.84–1.29)	0.73
	≥2	<140	68,956	1.40 (1.16–1.69)	***
		≥140	63,979	1.46 (1.32–1.78)	***
eGFR (ml/min/1.73m ²)	0	≥60	137,083	1 (ref)	
		<60	1,270	0.74 (0.18–2.96)	0.67
	1	≥60	128,860	1.09 (0.93–1.28)	0.26
		<60	2,108	2.14 (1.17–3.92)	0.01
	≥2	≥60	123,182	1.43 (1.22–1.67)	***
		<60	4,981	2.13 (1.46–3.12)	***

Models were adjusted for sex, age, ethnicity, Townsend score, smoking status, alcohol intake frequency, physical activity, BMI, and assessment centre location.

LTC = long-term condition; BMI = body mass index; eGFR = estimated glomerular filtration rate; guidelines = UK guidelines of 150 min/week moderate or 75 min/week vigorous physical activity.

***p<0.01.

<https://doi.org/10.1371/journal.pone.0238091.t003>

Discussion

Summary of key findings

This study showed that participants with multimorbidity (≥2 LTCs) had a 48% higher risk of a positive COVID-19 test, those with cardiometabolic multimorbidity had a 77% higher risk, and those with respiratory multimorbidity a 78% higher risk (albeit not statistically significant, $p = 0.02$), compared to those without that type of multimorbidity. Importantly, those from non-white ethnicities with multimorbidity had nearly three times the risk of having COVID-19 infection compared to those of white ethnicity, suggesting that those from minority ethnic groups with multimorbidity are at particular risk. COVID-19 prognostic factors appeared to have an additive effect by further increasing the risk of a positive COVID-19 test in those with multimorbidity.

Comparison with previous literature

Previous literature has suggested that the presence of single LTCs such as hypertension, diabetes, or COPD increase the risk of COVID-19 [33]. In an English primary care research cohort of 3,802 patients, confirmed COVID-19 infections were associated with male sex, black ethnicity, deprivation, chronic kidney disease, and urban setting [30]. A preprint report of linked primary care data on 17,425,445 adults in England, showed that older age, male sex, deprivation, and black and Asian ethnicity were associated with higher risk of COVID-19 related in-hospital deaths [11]. However, our study is the first to show a higher risk of a positive COVID-19 test in those with ≥2 LTCs and particularly in those with cardiometabolic multimorbidity.

It has also been suggested that the presence of multimorbidity could further increase the risk of adverse outcomes for people with COVID-19 [33]. Guan et al, in a cohort of 1,590 hospital patients with confirmed COVID-19, found a higher risk of a composite COVID-19 outcome (intensive care admission, invasive ventilation, or death) in those with 1 (HR 1.79 (95%CI 1.16–2.77)) and 2 (HR 2.59 (95%CI 1.61–4.17)) comorbidities [9]. However, while they provided details of specific LTCs most likely to be present, especially in severe cases of infection (hypertension, cardiovascular/cerebrovascular diseases, diabetes, hepatitis B infections, COPD, chronic kidney diseases and malignancy), they did not describe which patterns of multimorbidity were associated with the greatest risk. A report on 3,200 patients with COVID-19 from Italy showed that, of the 481 patients who died, 48.6% had 3 or more comorbidities. However, again, while it listed the specific LTCs associated with increased risk, such as ischaemic heart disease and diabetes, it did not describe which patterns of multimorbidity were associated with the highest risk [13].

Strengths and limitations

As a large prospective cohort with rich demographic, lifestyle, health, and anthropometric data linked to COVID-19 test results, UK Biobank provides a valuable opportunity to examine the predictors for COVID-19 [34, 35]. In particular, the rich data allowed examination of the risk of a positive COVID-19 test in those with multimorbidity and the influence of a range of known sociodemographic, lifestyle and physiological risk factors for COVID-19. However, our study has a number of limitations. Firstly, the proportion of UK Biobank participants with COVID-19 test data is currently low (1.05%) which resulted in wide confidence intervals for groups with few participants. Secondly, the denominator for the test group included all those who had a negative test result as well as those who were not tested at all. At the time for which COVID-19 test data are available, the strategy in the UK had been to only test those in hospital (emergency department and inpatient) settings. This means the positive COVID-19 participants are likely to have had sufficiently severe clinical signs and symptoms to justify hospital assessment and those with COVID-19 but with mild symptoms are less likely to have been tested. Our results are therefore likely to reflect the associations with more severe COVID-19 disease. It is not known if the associations identified in this study would be similar for those with milder COVID-19 disease. Thirdly, exposures and moderators examined here were assessed at baseline only and may have changed during follow up. Depending on the direction and level of change since recruitment, more up-to-date data on exposures (e.g. smoking, alcohol intake, physical activity, and post code of residence) could have provided different results. However, LTC and medication count are likely to have remained the same or increased with time and therefore our effect size estimates may be conservative. Fourthly, UK Biobank participants are not representative of the general population and are acknowledged to be mostly white British, more affluent, and healthier than the general population [36]. Consequently, absolute values may not be generalisable, however, effect size estimates will be and strongly agree with more representative cohorts [37]. Finally, participants in this study were aged between 48–86 years old and associations between multimorbidity and COVID-19 may be different for younger age groups. This may be particularly important for participants from more deprived backgrounds who are more likely to have multimorbidity at a younger age [38, 39].

Implications

Our work has clinical and practical implications as more countries navigate lifting COVID-19 restrictions. It demonstrates that multimorbidity, particularly cardiometabolic multimorbidity and polypharmacy, are strongly associated with COVID-19 infection and suggests that those who have multimorbidity coupled with additional risk factors, such as non-white ethnicity, are

at increased risk. Such individuals should be particularly stringent in adhering to preventive measures, such as physical distancing and hand hygiene. Our findings also have implications for clinicians, occupational health and employers when considering work-place environments, appropriate advice for patients, and adaptations that might be required to protect such staff.

Future research is needed to corroborate these findings in other countries and in people from different ethnic backgrounds. We know that patterns of multimorbidity differ across ethnic groups and have different associations with mortality, so this merits further investigation [40]. We also need to explore the implications of different patterns of multimorbidity on COVID-19 related health care outcomes in the short and long term.

Conclusion

This study suggests that multimorbidity, cardiometabolic disease, and polypharmacy are associated with COVID-19. Those with multimorbidity who were also of non-white ethnicity, from the most socioeconomically deprived backgrounds, those who were severely obese, or who had reduced renal function, had more than twice the risk of COVID-19 infection.

More work is required to develop risk stratification for COVID-19 in people with different patterns of multimorbidity in order to better define those individuals who would benefit from enhanced preventive measures in public, work, and residential spaces.

Supporting information

S1 Table. Cohort characteristics by COVID-19 testing.

(DOCX)

S2 Table. Relative risk of COVID-19 testing by multimorbidity (Poisson regression).

(DOCX)

S3 Table. Relative risk of COVID-19 testing by LTC category and prognostic factors.

(DOCX)

Acknowledgments

The authors would like to thank the participants of UK Biobank and the UK Biobank for access to this data.

Author Contributions

Conceptualization: Ross McQueenie, Hamish M. E. Foster, Bhautesh D. Jani, Srinivasa Vittal Katikireddi, Naveed Sattar, Jill P. Pell, Catherine A. O'Donnell, Frances S. Mair, Barbara I. Nicholl.

Formal analysis: Ross McQueenie.

Methodology: Ross McQueenie, Bhautesh D. Jani, Naveed Sattar, Jill P. Pell, Frederick K. Ho, Claire L. Niedzwiedz, Claire E. Hastie, Jana Anderson, Patrick B. Mark, Michael Sullivan, Catherine A. O'Donnell, Frances S. Mair, Barbara I. Nicholl.

Project administration: Hamish M. E. Foster, Barbara I. Nicholl.

Supervision: Bhautesh D. Jani, Catherine A. O'Donnell, Frances S. Mair, Barbara I. Nicholl.

Validation: Hamish M. E. Foster, Barbara I. Nicholl.

Visualization: Ross McQueenie, Hamish M. E. Foster, Bhautesh D. Jani, Frederick K. Ho, Catherine A. O'Donnell, Frances S. Mair, Barbara I. Nicholl.

Writing – original draft: Ross McQueenie, Hamish M. E. Foster, Catherine A. O'Donnell, Frances S. Mair, Barbara I. Nicholl.

Writing – review & editing: Ross McQueenie, Hamish M. E. Foster, Bhautesh D. Jani, Srinivasa Vittal Katikireddi, Naveed Sattar, Jill P. Pell, Frederick K. Ho, Claire L. Niedzwiedz, Claire E. Hastie, Jana Anderson, Patrick B. Mark, Michael Sullivan, Catherine A. O'Donnell, Frances S. Mair, Barbara I. Nicholl.

References

1. World Health Organisation: Coronavirus disease 2019 (COVID-19) Situation Report– 22. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2; 2020.
2. World Health Organisation Director-General's opening remarks at the media briefing on COVID-19–11 March 2020. 2020.
3. Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol.* 2020; 5(4):536–44. <https://doi.org/10.1038/s41564-020-0695-z> PMID: 32123347
4. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. *Journal of Medical Virology.* 2020.
5. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA.* 2020.
6. GLOBAL_HEALTH5050. COVID-19 sex-disaggregated data tracker 2020 [Available from: <https://globalhealth5050.org/covid19/>]
7. ONS. Coronavirus (COVID-19) related deaths by ethnic group, England and Wales: 2 March 2020 to 10 April 2020 (UK Office for National Statistics). 2020.
8. Sattar N, McInnes IB, McMurray JJV. Obesity a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. *Circulation.* 2020.
9. Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *European Respiratory Journal.* 2020; 55(5):2000547. <https://doi.org/10.1183/13993003.00547-2020> PMID: 32217650
10. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia—A systematic review, meta-analysis, and meta-regression. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews.* 2020; 14(4):395–403.
11. Collaborative TO. MedRxiv preprint—OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. 2020.
12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020; 395(10223):497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5) PMID: 31986264
13. ISS. Istituto Superiore di Sanità: Characteristics of COVID-19 patients dying in Italy Report based on available data on March 26th, 2020. 2020.
14. Centers for Disease Control and Prevention: Coronavirus Disease 2019 (COVID-19): People Who Are at Higher Risk for Severe Illness. 2020.
15. UK Cabinet Office: Staying at home and away from others (social distancing) 2020.
16. PHE. Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19. 2020.
17. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ.* 2020; 369:m1985. <https://doi.org/10.1136/bmj.m1985> PMID: 32444460
18. Tran J, Norton R, Conrad N, Rahimian F, Canoy D, Nazarzadeh M, et al. Patterns and temporal trends of comorbidity among adult patients with incident cardiovascular disease in the UK between 2000 and 2014: A population-based cohort study. *PLoS Med.* 2018; 15(3):e1002513. <https://doi.org/10.1371/journal.pmed.1002513> PMID: 29509757
19. Arokiasamy P, Uttamacharya U, Jain K, Biritwum RB, Yawson AE, Wu F, et al. The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on

- global ageing and adult health (SAGE) reveal? *BMC Med.* 2015; 13:178. <https://doi.org/10.1186/s12916-015-0402-8> PMID: 26239481
20. Garin N, Koyanagi A, Chatterji S, Tyrovolas S, Olaya B, Leonardi M, et al. Global Multimorbidity Patterns: A Cross-Sectional, Population-Based, Multi-Country Study. *J Gerontol A Biol Sci Med Sci.* 2016; 71(2):205–14. <https://doi.org/10.1093/gerona/glv128> PMID: 26419978
 21. Jani BD, Hanlon P, Nicholl BI, McQueenie R, Gallacher KI, Lee D, et al. Relationship between multimorbidity, demographic factors and mortality: findings from the UK Biobank cohort. *BMC Med.* 2019; 17(1):74. <https://doi.org/10.1186/s12916-019-1305-x> PMID: 30967141
 22. Corsonello A, Pedone C, Corica F, Incalzi RA. Polypharmacy in elderly patients at discharge from the acute care hospital. *Ther Clin Risk Manag.* 2007; 3(1):197–203. <https://doi.org/10.2147/tcrm.2007.3.1.197> PMID: 18360627
 23. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. *BMC Med.* 2015; 13:74. <https://doi.org/10.1186/s12916-015-0322-7> PMID: 25889849
 24. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* 2015; 12(3):e1001779. <https://doi.org/10.1371/journal.pmed.1001779> PMID: 25826379
 25. UKBiobank. COVID-19 test results data 2020 [Available from: http://biobank.ndph.ox.ac.uk/ukb/exinfo.cgi?src=COVID19_tests].
 26. Townsend P, Philimore, P., Beattie, A. Health and deprivation: inequality and the North.: Croom Helm; 1987.
 27. IPAQ. IPAQ scoring protocol 2005 [Available from: <https://sites.google.com/site/theipaq/scoring-protocol>].
 28. Elliott P, Peakman TC. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. *International Journal of Epidemiology.* 2008; 37(2):234–44. <https://doi.org/10.1093/ije/dym276> PMID: 18381398
 29. UK Chief Medical Officers' Physical Activity Guidelines 2019.
 30. De Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. *The Lancet Infectious Diseases.* 2020.
 31. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009; 150(9):604–12. <https://doi.org/10.7326/0003-4819-150-9-200905050-00006> PMID: 19414839
 32. Zou GY, Donner A. Extension of the modified Poisson regression model to prospective studies with correlated binary data. *Stat Methods Med Res.* 2013; 22(6):661–70. <https://doi.org/10.1177/0962280211427759> PMID: 22072596
 33. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. *J Infect.* 2020.
 34. Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. *Diabetes Metab Syndr.* 2020; 14(4):561–5. <https://doi.org/10.1016/j.dsx.2020.04.050> PMID: 32413819
 35. Niedzwiedz CL, O'Donnell CA, Jani BD, Demou E, Ho FK, Celis-Morales C, et al. Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank. *medRxiv.* 2020:2020.04.22.20075663.
 36. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol.* 2017; 186(9):1026–34. <https://doi.org/10.1093/aje/kwx246> PMID: 28641372
 37. Batty GD, Gale CR, Kivimäki M, Deary IJ, Bell S. Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis. *BMJ.* 2020:m131.
 38. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet.* 2012; 380(9836):37–43. [https://doi.org/10.1016/S0140-6736\(12\)60240-2](https://doi.org/10.1016/S0140-6736(12)60240-2) PMID: 22579043
 39. Pathirana TI, Jackson CA. Socioeconomic status and multimorbidity: a systematic review and meta-analysis. *Aust N Z J Public Health.* 2018; 42(2):186–94. <https://doi.org/10.1111/1753-6405.12762> PMID: 29442409
 40. Chiang JI, Hanlon P, Li TC, Jani BD, Manski-Nankervis JA, Furler J, et al. Multimorbidity, mortality, and HbA1c in type 2 diabetes: A cohort study with UK and Taiwanese cohorts. *PLoS Med.* 2020; 17(5): e1003094. <https://doi.org/10.1371/journal.pmed.1003094> PMID: 32379755